Helix

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

Retrieved on: 
화요일, 5월 14, 2024
Security (finance), BCDA, Partnership, Patient, Angina, Arrhythmia, CMS, Medicare, Chest pain, Risk, Heart, Heart failure, THT, FDA, IND, Helix, Therapy, Trial of the century, Hospital, Exercise, Incidence, Mortality, Research, Stroke, Quality of life, Splenic infarction, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • The interim results from this study, with 110 of the 115 randomized patients, were presented at the Technology and Heart Failure Therapeutics (THT) meeting on March 4, 2024.
  • This study was activated in the first quarter of 2024 with a goal of completing enrollment two years after the first patient is enrolled.
  • First Quarter 2024 Financial Results:
    Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.

NJOY Submits Premarket Tobacco Product Applications to the FDA for NJOY ACE 2.0 Featuring Bluetooth®-enabled Access Restriction Technology

Retrieved on: 
월요일, 5월 20, 2024
Wearables, Mobile Technology, Mobile, Wireless, Technology, FDA, Tobacco, Software, Biometrics, Health, Retail, Consumer Electronics, NJOY, AB InBev, Risk, Marketing, MDO, Food, Investment, MDOS, APPH, Helix, Smoker, Public, Horizon, Heated tobacco product, Senior, MST, Annual report, ABI, AGDC, PM

The company also re-submitted PMTAs for Blueberry and Watermelon pod products that work exclusively with the NJOY ACE 2.0 device.

Key Points: 
  • The company also re-submitted PMTAs for Blueberry and Watermelon pod products that work exclusively with the NJOY ACE 2.0 device.
  • NJOY ACE 2.0 includes critical technology features to prevent underage access to flavored NJOY products, while also responsibly providing flavored options for adult smokers and vapers,” said Shannon Leistra, President & Chief Executive Officer of NJOY.
  • NJOY ACE currently remains the only pod-based e-vapor product with marketing authorization from the FDA.
  • On April 26, 2022, the FDA authorized the NJOY ACE device and NJOY ACE Classic Tobacco (2.4% and 5%) and Rich Tobacco (5%) pods as APPH.

Altria Holds 2024 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $0.98 Per Share

Retrieved on: 
목요일, 5월 16, 2024
Tobacco, Retail, Other Retail, PwC, NJOY, AB InBev, Food, Investment, Annual general meeting, FDA, Helix, Smoker, Heated tobacco product, Horizon, Marketing, Annual, MST, ABI, Webcast, PM

Altria Group, Inc. (Altria) (NYSE: MO) held our 2024 Annual Meeting of Shareholders (Annual Meeting) today.

Key Points: 
  • Altria Group, Inc. (Altria) (NYSE: MO) held our 2024 Annual Meeting of Shareholders (Annual Meeting) today.
  • During the Annual Meeting, Billy Gifford, Altria’s Chief Executive Officer, provided brief remarks and addressed shareholder questions.
  • Following the Annual Meeting, our Board declared a regular quarterly dividend of $0.98 per share, payable on July 10, 2024, to shareholders of record as of June 14, 2024.
  • Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

Soluna Launches New AI Cloud Service in Collaboration with Leading High Performance Computing Company

Retrieved on: 
수요일, 5월 8, 2024
Green Technology, Security, Environment, Artificial Intelligence, Sustainability, Software, Networks, Internet, Hardware, Electronic Design Automation, Professional Services, Data Management, Technology, Other Energy, Utilities, Cryptocurrency, Alternative Energy, Energy, Apps, Applications, Bitcoin, Cloud, AI, H100, Helix, Security (finance), OEM, Artificial intelligence, Thony Belizaire, NVIDIA, Generative, Renewable energy, Strategy, Annual report, Partnership, Video game

As part of the collaboration, Soluna will work with the Strategic Partner to deliver powerful, energy-efficient supercomputers for large-scale AI projects.

Key Points: 
  • As part of the collaboration, Soluna will work with the Strategic Partner to deliver powerful, energy-efficient supercomputers for large-scale AI projects.
  • Soluna Cloud will begin offering its services by leveraging the Strategic Partner’s renewable- powered high performance data centers.
  • John Belizaire, CEO of Soluna, expressed his excitement about teaming up with a leading global enterprise computing company, stating, “We are honored to enter this collaboration to launch Soluna Cloud.
  • With a growing pipeline of AI Customers interested in its AI Cloud, Soluna anticipates significant growth opportunities in the coming months.

Red Cat Successfully Passes Field Testing with Doodle Labs Against Electronic Warfare Technology in Ukraine

Retrieved on: 
목요일, 4월 25, 2024
Defense Innovation Unit, Radio, Teledyne Technologies, Blue, Helix, Software, Partnership, Teledyne FLIR, SRR, Government, RCAT, Ocean Power Technologies, SAN

SAN JUAN, Puerto Rico, April 25, 2024 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) ("Red Cat"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announced it has successfully passed electronic warfare (EW) testing in Ukraine with Doodle Labs.

Key Points: 
  • SAN JUAN, Puerto Rico, April 25, 2024 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) ("Red Cat"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announced it has successfully passed electronic warfare (EW) testing in Ukraine with Doodle Labs.
  • The successful test is part of a continuous innovation cycle that began in May 2023 with a partnership between Doodle Labs and Red Cat for its U.S. Army Short Range Reconnaissance (SRR) program prototype.
  • The ongoing partnership between Red Cat and Doodle Labs is addressing the growing need by the U.S. and its allies for small, autonomous, and attritable drones equipped with anti-jamming radios capable of operating in electronic warfare.
  • Teal systems with Doodle Labs frequency-hopping radios can evade jamming attempts and are usable in multi-domain environments for surveillance and swarming operations.

BMC to Acquire Netreo

Retrieved on: 
화요일, 4월 16, 2024
BMC, Risk, NPMD, Helix, APM, DevOps, ITIM, Acquisition, Root cause analysis, Overalls, Asset management

HOUSTON , April 16, 2024 /PRNewswire/ -- BMC, a global leader in software solutions for the Autonomous Digital Enterprise, today announced the signing of a definitive agreement to acquire Netreo, the award-winning provider of smart and secure IT network and application observability solutions. With Netreo, the BMC Helix platform will provide customers with a full-stack, open observability, and AIOps solution. The deal is expected to close in the first half of 2024, subject to customary closing conditions. Financial terms of the transaction were not disclosed. 

Key Points: 
  • HOUSTON , April 16, 2024 /PRNewswire/ -- BMC , a global leader in software solutions for the Autonomous Digital Enterprise , today announced the signing of a definitive agreement to acquire Netreo , the award-winning provider of smart and secure IT network and application observability solutions.
  • With Netreo, the BMC Helix platform will provide customers with a full-stack, open observability, and AIOps solution.
  • Netreo's OpenTelemetry-based observability, APM, and NPMD are a perfect complement to the industry recognized BMC Helix observability, AIOps, and ServiceOps solutions," said Margaret Lee, senior vice president and general manager of Digital Service and Operations Management at BMC.
  • With this acquisition, BMC continues to invest in innovation – from IT operations management to service management, data and application workflow automation, and mainframe management.

FDA Grants Orphan Drug Designation for the Treatment of Scleroderma

Retrieved on: 
목요일, 4월 11, 2024
Collagen, Pain, FDA, Mortality, University, Patient, RFU, Systemic scleroderma, Risk, Skin, Food, Death, Helix, BLR, Research, Disease, Scleroderma, Rheumatology, Fatigue, Fibrosis, Public, Rheumatism, Multimedia, Myofibroblast, Pharmaceutical industry

NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ -- BLR Bio, an emerging biotechnology company in Rosalind Franklin University's Helix 51 biomedical incubator , announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma.

Key Points: 
  • NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ -- BLR Bio, an emerging biotechnology company in Rosalind Franklin University's Helix 51 biomedical incubator , announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma.
  • Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the U.S.
  • "The FDA's granting of Orphan Drug Designation to BLR-200 highlights the urgent need for new and innovative therapeutic options for patients afflicted with the disease."
  • Dr. Ronald Kaplan, RFU executive vice president for research, said the orphan designation represents an important milestone in the development of BLR Bio's drug candidate.

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Retrieved on: 
수요일, 3월 27, 2024
Research, Finkelstein, Arrhythmia, Stroke, Annual report, Certification, Myocardial infarction, BCDA, Partnership, Patient, The Study, Morph, Mortality, Form 10-K, Security (finance), Death, Heart transplantation, Quality of life, Doctor of Philosophy, Heart failure, Therapy, Heart, Safety, Data, Medicare, FDA, Helix, Arrest, Hospital, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • The Company anticipates completing follow-up in the trial and preparing this dataset on 115 randomized patients enrolled with a minimum of one-year follow-up for final lock in the fourth quarter of 2024.
  • BioCardia has had discussions on partnering its CardiAMP therapy for other clinical indications and continues to explore partnerships worldwide.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call.

Helix Announces First Quarter Earnings Release Date and Conference Call Information

Retrieved on: 
금요일, 4월 5, 2024
Robotics, Other Energy, Technology, Oil, Gas, Alternative Energy, Energy, Staffeldt, Helix Energy Solutions Group, Webcast, HLX, Helix, Central Time

Helix Energy Solutions Group, Inc. (NYSE: HLX) will issue a press release reporting its first quarter 2024 results on Wednesday, April 24, 2024, after the close of business.

Key Points: 
  • Helix Energy Solutions Group, Inc. (NYSE: HLX) will issue a press release reporting its first quarter 2024 results on Wednesday, April 24, 2024, after the close of business.
  • The press release and associated slide presentation will be available on Helix's website, www.helixesg.com .
  • Helix will review its first quarter 2024 results on Thursday, April 25, 2024, at 9:00 a.m. Central Time via a live webcast and teleconference.
  • The live webcast will be available on our website under "For the Investor."

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
화요일, 3월 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.